TG Therapeutics, Inc.
TGTX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $180 | $93 | $102 | $299 |
| Short-Term Investments | $131 | $125 | $59 | $16 |
| Receivables | $129 | $51 | $0 | $1 |
| Inventory | $110 | $40 | $0 | $0 |
| Other Curr. Assets | $16 | $10 | $7 | $15 |
| Total Curr. Assets | $566 | $318 | $168 | $331 |
| Property Plant & Equip (Net) | $7 | $8 | $11 | $11 |
| Goodwill | $0 | $1 | $1 | $1 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $1 | $0 | $12 | $36 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $3 | $3 | $1 | $1 |
| Total NC Assets | $11 | $12 | $25 | $49 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $578 | $330 | $194 | $380 |
| Liabilities | – | – | – | – |
| Payables | $0 | $0 | $0 | $0 |
| Short-Term Debt | $1 | $1 | $2 | $2 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $11 | $0 | $0 | $0 |
| Other Curr. Liab. | $78 | $52 | $52 | $63 |
| Total Curr. Liab. | $91 | $54 | $53 | $65 |
| LT Debt | $253 | $109 | $81 | $77 |
| Deferred Rev, NC | $12 | $6 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $265 | $115 | $82 | $77 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $9 | $11 | $12 | $11 |
| Total Liabilities | $355 | $169 | $135 | $142 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$1,529 | -$1,553 | -$1,527 | -$1,329 |
| AOCI | $0 | $0 | $0 | $0 |
| Other Equity | $1,751 | $1,713 | $1,585 | $1,566 |
| Total Equity | $222 | $161 | $59 | $237 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $578 | $330 | $194 | $380 |
| Net Debt | $74 | $18 | -$19 | -$220 |